Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTH120 in adult males with Fragile X syndrome
2025-522972-97-00Phase 2Authorised
- Sponsor
- CONNECTA Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Fragile X syndrome (FXS) comparing CTH120 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events and Treatment-emergent potentially clinically significant abnormalities. Planned start Dec 2025; status: authorised.
02
Drugs
CTH120
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on 2025-522972-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522972-97-00.